|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.98/--
|
企业价值
1.14B
|
资产负债 |
每股账面净值
4.23
|
现金流量 |
现金流量率
0.01
|
损益表 |
收益
54.00M
|
每股收益
0.89
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/21 19:08 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. |